Research programme: steroid 11-beta- hydroxylase inhibitors - ElexoPharm
Alternative Names: CYP11B1 inhibitors - ElexoPharmLatest Information Update: 07 Sep 2023
At a glance
- Originator ElexoPharm GmbH
- Class
- Mechanism of Action Steroid 11-beta-hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cushing syndrome
Most Recent Events
- 07 Sep 2023 Discontinued - Preclinical for Cushing syndrome in Germany (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cushing-syndrome in Germany
- 19 Jul 2016 Preclinical trials in Cushing's syndrome in Germany (unspecified route)